Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMIX Autonomix Medical	$1.12 +1.8%	$1.33	$0.96 ▼ $21.49	$6.51M	-2.96	261,264 shs	251,857 shs
AVGR Avinger	$0.47	$0.47	$0.36 ▼ $1.93	$1.57M	1.29	1.46 million shs	N/A
NUWE Nuwellis	$5.10 -1.5%	$8.51	$4.82 ▼ $175.98	$4.68M	N/A	226,489 shs	21,971 shs
XAGE Longevity Health	$2.54 -1.6%	$3.00	$2.15 ▼ $38.10	$4.60M	0.51	30,075 shs	6,707 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMIX Autonomix Medical	-6.78%	+8.91%	-13.39%	-31.25%	-90.44%
AVGR Avinger	0.00%	0.00%	0.00%	0.00%	-56.51%
NUWE Nuwellis	+0.58%	-2.08%	-50.76%	-85.85%	-90.36%
XAGE Longevity Health	-5.49%	+1.57%	-24.34%	+257,999,900.00%	+257,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMIX Autonomix Medical	2.8168 of 5 stars	3.5	2.0	0.0	0.0	2.5	1.7	1.3
AVGR Avinger	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NUWE Nuwellis	0.8957 of 5 stars	0.0	4.0	0.0	0.0	1.5	1.7	0.6
XAGE Longevity Health	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMIX Autonomix Medical	3.00	Buy	$16.50	1,373.21% Upside
AVGR Avinger	0.00	N/A	N/A	N/A
NUWE Nuwellis	3.00	Buy	N/A	N/A
XAGE Longevity Health	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMIX Autonomix Medical	N/A	N/A	N/A	N/A	$1.19 per share	N/A
AVGR Avinger	$7.65M	0.21	N/A	N/A	($4.53) per share	-0.10
NUWE Nuwellis	$8.74M	0.53	N/A	N/A	($9.93) per share	-0.51
XAGE Longevity Health	$50K	90.42	N/A	N/A	($2.10) per share	-1.21

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMIX Autonomix Medical	-$11.41M	-$5.74	N/A	N/A	N/A	N/A	-172.93%	-133.39%	11/14/2025 (Estimated)
AVGR Avinger	-$18.32M	-$11.06	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NUWE Nuwellis	-$11.16M	-$35.36	N/A	N/A	N/A	-176.45%	-1,424.01%	-187.69%	11/10/2025 (Estimated)
XAGE Longevity Health	-$10.37M	N/A	0.00	∞	N/A	-682.67%	N/A	-261.90%	N/A

Latest AVGR, AMIX, XAGE, and NUWE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	XAGE Longevity Health	N/A	-$1.56	N/A	-$1.56	N/A	$0.50 million
8/13/2025	Q1 2026	AMIX Autonomix Medical	-$0.98	-$1.07	-$0.09	-$1.07	N/A	N/A
8/12/2025	Q2 2025	NUWE Nuwellis	-$0.45	-$60.99	-$60.54	-$60.99	$2.20 million	$1.73 million
5/29/2025	Q4 2025	AMIX Autonomix Medical	N/A	-$0.74	N/A	-$0.74	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMIX Autonomix Medical	N/A	N/A	N/A	N/A	N/A
AVGR Avinger	N/A	N/A	N/A	N/A	N/A
NUWE Nuwellis	N/A	N/A	N/A	N/A	N/A
XAGE Longevity Health	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMIX Autonomix Medical	N/A	4.57	4.57
AVGR Avinger	N/A	N/A	N/A
NUWE Nuwellis	N/A	2.16	1.64
XAGE Longevity Health	N/A	0.47	0.30

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMIX Autonomix Medical	10.78%
AVGR Avinger	18.30%
NUWE Nuwellis	3.13%
XAGE Longevity Health	24.22%

Insider Ownership

Company	Insider Ownership
AMIX Autonomix Medical	32.40%
AVGR Avinger	42.80%
NUWE Nuwellis	20.08%
XAGE Longevity Health	29.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMIX Autonomix Medical	1	5.92 million	4.00 million	N/A
AVGR Avinger	70	3.31 million	1.89 million	Not Optionable
NUWE Nuwellis	70	900,000	722,000	Not Optionable
XAGE Longevity Health	14	1.78 million	1.27 million	N/A

AVGR, AMIX, XAGE, and NUWE Headlines

Recent News About These Companies

Longevity Health (NASDAQ:XAGE) versus TransEnterix (OTCMKTS:TRXDW) Financial Contrast

August 19, 2025 | americanbankingnews.com

Why Longevity Health Stock Is Skyrocketing Today

July 15, 2025 | benzinga.com

Why Longevity Health Stock Is Skyrocketing Today

July 15, 2025 | benzinga.com

Why did XAGE Stock Surge in Today’s Premarket Trading?

July 15, 2025 | tokenist.comT

Longevity Health Holdings, Inc.: Longevity Health Holdings Announces Merger with THPlasma and Termination of 20/20 BioLabs Transaction

July 15, 2025 | finanznachrichten.de

Longevity Health Holdings to Merge With True Health

July 15, 2025 | marketwatch.com

Longevity Health stock soars after merger with THPlasma in all-stock deal

July 15, 2025 | investing.com

Longevity Health Holdings Announces Merger with THPlasma and Termination of 20/20 BioLabs Transaction

July 14, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVGR, AMIX, XAGE, and NUWE Company Descriptions

Autonomix Medical NASDAQ:AMIX

$1.12 +0.02 (+1.82%)

Closing price 04:00 PM Eastern

Extended Trading

$1.10 -0.02 (-1.79%)

As of 07:53 PM Eastern

Autonomix Medical, Inc., a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.

Avinger NASDAQ:AVGR

Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany. The company develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. Its lumivascular products comprise Lightbox imaging consoles; the Ocelot and Tigereye family of devices, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. The company is also developing IMAGE-BTK for the treatment of PAD lesions below-the-knee. It markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists. The company was incorporated in 2007 and is based in Redwood City, California.

Nuwellis NASDAQ:NUWE

$5.10 -0.08 (-1.54%)

Closing price 04:00 PM Eastern

Extended Trading

$5.11 +0.01 (+0.10%)

As of 06:37 PM Eastern

Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company offers Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure. Its Aquadex FlexFlow system includes a console, disposable blood circuit set, and disposable catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors in Austria, Belarus, Brazil, Colombia, the Czech Republic, Germany, Greece, Hong Kong, India, Israel, Italy, Panama, Romania, Singapore, Slovakia, Spain, Switzerland, Thailand, the United Arab Emirates, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.

Longevity Health NASDAQ:XAGE

$2.54 -0.04 (-1.55%)

As of 02:53 PM Eastern

Carmell Therapeutics Corporation focuses on the development of plasma-based bioactive material (PBM) to stimulate tissue repair or growth after injury, disease, and aging. Its lead product candidate is CT-101 bone healing accelerant for tibia fracture healing, foot/ankle fusion, spinal fusion, dental bone graft substitute, and bone void filler; and tissue healing accelerant for androgenetic alopecia and chronic wound healing. The company was founded in 2008 and is based in Pittsburgh, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time